{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:09:46Z","timestamp":1792534186020,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR127337"],"award-info":[{"award-number":["NIHR127337"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1171206"],"award-info":[{"award-number":["GNT1171206"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed to manage anxiety in adults with an autism diagnosis. However, their effectiveness and adverse effect profile in the autistic population are not well known. This trial aims to determine the effectiveness and cost-effectiveness of the SSRI sertraline in reducing symptoms of anxiety and improving quality of life in adults with a diagnosis of autism compared with placebo and to quantify any adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>STRATA is a two-parallel group, multi-centre, pragmatic, double-blind, randomised placebo-controlled trial with allocation at the level of the individual. It will be delivered through recruiting sites with autism services in 4 regional centres in the United Kingdom (UK) and 1 in Australia. Adults with an autism diagnosis and a Generalised Anxiety Disorder Assessment (GAD-7) score\u2009\u2265\u200910 at screening will be randomised 1:1 to either 25\u00a0mg sertraline or placebo, with subsequent flexible dose titration up to 200\u00a0mg. The primary outcome is GAD-7 scores at 16\u00a0weeks post-randomisation. Secondary outcomes include adverse effects, proportionate change in GAD-7 scores including 50% reduction, social anxiety, obsessive-compulsive symptoms, panic attacks, repetitive behaviours, meltdowns, depressive symptoms, composite depression and anxiety, functioning and disability and quality of life. Carer burden will be assessed in a linked carer sub-study. Outcome data will be collected using online\/paper methods via video call, face-to-face or telephone according to participant preference at 16, 24 and 52\u00a0weeks post-randomisation, with brief safety checks and data collection at 1\u20132, 4, 8, 12 and 36\u00a0weeks. An economic evaluation to study the cost-effectiveness of sertraline vs placebo and a QuinteT Recruitment Intervention (QRI) to optimise recruitment and informed consent are embedded within the trial. Qualitative interviews at various times during the study will explore experiences of participating and taking the trial medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Results from this study should help autistic adults and their clinicians make evidence-based decisions on the use of sertraline for managing anxiety in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ISRCTN,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN15984604\">ISRCTN15984604<\/jats:ext-link>\n                      . Registered on 08 February 2021. EudraCT 2019-004312-66. ANZCTR ACTRN12621000801819. Registered on 07 April 2021.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07847-3","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T06:02:56Z","timestamp":1704952976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sertraline for anxiety in adults with a diagnosis of autism (STRATA): study protocol for a pragmatic, multicentre, double-blind, placebo-controlled randomised controlled trial"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7239-3523","authenticated-orcid":false,"given":"Dheeraj","family":"Rai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonora","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade Eloise","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regi","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traolach","family":"Brugha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Cochrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Del Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Glasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine K.","family":"Hatch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"MacNeill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximiliano Vazquez","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba X.","family":"Realpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Starkstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Thorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the STRATA autistic advisory group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Wiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"issue":"9920","key":"7847_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(13)61539-1","volume":"383","author":"MC Lai","year":"2014","unstructured":"Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014;383(9920):896\u2013910.","journal-title":"Lancet"},{"issue":"4","key":"7847_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1017\/S0033291718002283","volume":"49","author":"MJ Hollocks","year":"2019","unstructured":"Hollocks MJ, Lerh JW, Magiati I, Meiser-Stedman R, Brugha TS. Anxiety and depression in adults with autism spectrum disorder: a systematic review and meta-analysis. Psychol Med. 2019;49(4):559\u201372.","journal-title":"Psychol Med"},{"issue":"1","key":"7847_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s10803-019-04234-3","volume":"50","author":"V Nimmo-Smith","year":"2020","unstructured":"Nimmo-Smith V, Heuvelman H, Dalman C, Lundberg M, Idring S, Carpenter P, Magnusson C, Rai D. Anxiety disorders in adults with autism spectrum disorder: a population-based study. J Autism Dev Disord. 2020;50(1):308\u201318.","journal-title":"J Autism Dev Disord"},{"issue":"4","key":"7847_CR4","doi-asserted-by":"publisher","first-page":"e181465","DOI":"10.1001\/jamanetworkopen.2018.1465","volume":"1","author":"D Rai","year":"2018","unstructured":"Rai D, Heuvelman H, Dalman C, Culpin I, Lundberg M, Carpenter P, Magnusson C. Association between autism spectrum disorders with or without intellectual disability and depression in young adulthood. JAMA Netw Open. 2018;1(4):e181465.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"7847_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S2215-0366(19)30289-5","volume":"6","author":"MC Lai","year":"2019","unstructured":"Lai MC, Kassee C, Besney R, Bonato S, Hull L, Mandy W, Szatmari P, Ameis SH. Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(10):819\u201329.","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"7847_CR6","first-page":"1","volume":"53","author":"JFG Underwood","year":"2022","unstructured":"Underwood JFG, DelPozo-Banos M, Frizzati A, Rai D, John A, Hall J. Neurological and psychiatric disorders among autistic adults: a population healthcare record study. Psychol Med. 2022;53(12):1\u201311.","journal-title":"Psychol Med"},{"issue":"3","key":"7847_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1192\/bjp.bp.114.160192","volume":"208","author":"T Hirvikoski","year":"2016","unstructured":"Hirvikoski T, Mittendorfer-Rutz E, Boman M, Larsson H, Lichtenstein P, Bolte S. Premature mortality in autism spectrum disorder. Br J Psychiatry. 2016;208(3):232\u20138.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"7847_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/13623613221117931","volume":"27","author":"A Linden","year":"2023","unstructured":"Linden A, Best L, Elise F, Roberts D, Branagan A, Tay YBE, Crane L, Cusack J, Davidson B, Davidson I, et al. Benefits and harms of interventions to improve anxiety, depression, and other mental health outcomes for autistic people: a systematic review and network meta-analysis of randomised controlled trials. Autism. 2023;27(1):7\u201330.","journal-title":"Autism"},{"issue":"11","key":"7847_CR9","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1007\/s10803-014-2141-7","volume":"44","author":"CM Kerns","year":"2014","unstructured":"Kerns CM, Kendall PC, Berry L, Souders MC, Franklin ME, Schultz RT, Miller J, Herrington J. Traditional and atypical presentations of anxiety in youth with autism spectrum disorder. J Autism Dev Disord. 2014;44(11):2851\u201361.","journal-title":"J Autism Dev Disord"},{"issue":"12","key":"7847_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11920-017-0846-y","volume":"19","author":"V Postorino","year":"2017","unstructured":"Postorino V, Kerns CM, Vivanti G, Bradshaw J, Siracusano M, Mazzone L. Anxiety disorders and obsessive-compulsive disorder in individuals with autism spectrum disorder. Curr Psychiatry Rep. 2017;19(12):92.","journal-title":"Curr Psychiatry Rep"},{"issue":"5","key":"7847_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","volume":"28","author":"DS Baldwin","year":"2014","unstructured":"Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403\u201339.","journal-title":"J Psychopharmacol"},{"key":"7847_CR12","volume-title":"South London and Maudsley NHS Trust: The Maudsley prescribing guidelines in psychiatry","author":"D Taylor","year":"2015","unstructured":"Taylor D, Paton C, Kapur S. South London and Maudsley NHS Trust: The Maudsley prescribing guidelines in psychiatry. 12th ed. Chichester, West Sussex; Hoboken, NJ: John Wiley &; Sons Inc; 2015.","edition":"12"},{"issue":"11","key":"7847_CR13","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2215-0366(19)30366-9","volume":"6","author":"G Lewis","year":"2019","unstructured":"Lewis G, Duffy L, Ades A, Amos R, Araya R, Brabyn S, Button KS, Churchill R, Derrick C, Dowrick C, et al. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial. Lancet Psychiatry. 2019;6(11):903\u201314.","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"7847_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1192\/apt.7.4.275","volume":"7","author":"A Scott","year":"2001","unstructured":"Scott A, Davidson A, Palmer K. Antidepressant drugs in the treatment of anxiety disorders. Adv Psychiatr Treat. 2001;7(4):275\u201382.","journal-title":"Adv Psychiatr Treat"},{"issue":"12","key":"7847_CR15","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.4088\/JCP.v65n1216","volume":"65","author":"JC Ballenger","year":"2004","unstructured":"Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry. 2004;65(12):1696\u2013707.","journal-title":"J Clin Psychiatry"},{"key":"7847_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1192\/bjp.173.1.54","volume":"173","author":"PD Londborg","year":"1998","unstructured":"Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C. Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry. 1998;173:54\u201360.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"7847_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/acps.12644","volume":"135","author":"K Jobski","year":"2017","unstructured":"Jobski K, Hofer J, Hoffmann F, Bachmann C. Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review. Acta Psychiatr Scand. 2017;135(1):8\u201328.","journal-title":"Acta Psychiatr Scand"},{"key":"7847_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.neuroscience.2015.11.010","volume":"321","author":"CL Muller","year":"2016","unstructured":"Muller CL, Anacker AMJ, Veenstra-VanderWeele J. The serotonin system in autism spectrum disorder: from biomarker to animal models. Neuroscience. 2016;321:24\u201341.","journal-title":"Neuroscience"},{"issue":"6","key":"7847_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.euroneuro.2014.02.004","volume":"24","author":"S Gabriele","year":"2014","unstructured":"Gabriele S, Sacco R, Persico AM. Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2014;24(6):919\u201329.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"7847_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1017\/S1461145701002280","volume":"4","author":"MS Buchsbaum","year":"2001","unstructured":"Buchsbaum MS, Hollander E, Haznedar MM, Tang C, Spiegel-Cohen J, Wei TC, Solimando A, Buchsbaum BR, Robins D, Bienstock C, et al. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol. 2001;4(2):119\u201325.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"7847_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881117741766","volume":"32","author":"OD Howes","year":"2018","unstructured":"Howes OD, Rogdaki M, Findon JL, Wichers RH, Charman T, King BH, Loth E, McAlonan GM, McCracken JT, Parr JR, et al. Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol. 2018;32(1):3\u201329.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"7847_CR22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1176\/appi.ajp.2011.10050764","volume":"169","author":"E Hollander","year":"2012","unstructured":"Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, Wasserman S, Swanson E, Settipani C. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry. 2012;169(3):292\u20139.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"7847_CR23","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/archpsyc.1996.01830110037005","volume":"53","author":"CJ McDougle","year":"1996","unstructured":"McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996;53(11):1001\u20138.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"7847_CR24","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1192\/bjo.2021.1003","volume":"7","author":"S Deb","year":"2021","unstructured":"Deb S, Roy M, Lee R, Majid M, Limbu B, Santambrogio J, Roy A, Bertelli MO. Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: systematic review and meta-analysis. BJPsych Open. 2021;7(6):e179.","journal-title":"BJPsych Open"},{"key":"7847_CR25","unstructured":"Autistica and James Lind Alliance Priority Setting Partnership: Autism Top 10 priorities. https:\/\/www.jla.nihr.ac.uk\/priority-setting-partnerships\/autism\/top-10-priorities\/. Accessed 20 Sept 2023."},{"issue":"10","key":"7847_CR26","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092\u20137.","journal-title":"Arch Intern Med"},{"issue":"1","key":"7847_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13063-016-1391-4","volume":"17","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Rooshenas L, Jepson M, Elliott D, Wade J, Avery K, Mills N, Wilson C, Paramasivan S, Blazeby JM. Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI). Trials. 2016;17(1):283.","journal-title":"Trials"},{"key":"7847_CR28","unstructured":"STRATA Study Sites. https:\/\/strata.blogs.bristol.ac.uk\/strata-sites\/. Accessed 20 Sept 2023."},{"issue":"2","key":"7847_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1192\/bjp.bp.110.091223","volume":"200","author":"NJ Wiles","year":"2012","unstructured":"Wiles NJ, Mulligan J, Peters TJ, Cowen PJ, Mason V, Nutt D, Sharp D, Tallon D, Thomas L, O\u2019Donovan MC, et al. Severity of depression and response to antidepressants: GENPOD randomised controlled trial. Br J Psychiatry. 2012;200(2):130\u20136.","journal-title":"Br J Psychiatry"},{"key":"7847_CR30","unstructured":"STRATA: Information about sertraline. https:\/\/strata.blogs.bristol.ac.uk\/information-about-sertraline\/. Accessed 20 Sept 2023."},{"issue":"6","key":"7847_CR31","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1177\/1362361319889272","volume":"24","author":"A Russell","year":"2020","unstructured":"Russell A, Gaunt DM, Cooper K, Barton S, Horwood J, Kessler D, Metcalfe C, Ensum I, Ingham B, Parr JR, et al. The feasibility of low-intensity psychological therapy for depression co-occurring with autism in adults: The Autism Depression Trial (ADEPT) - a pilot randomised controlled trial. Autism. 2020;24(6):1360\u201372.","journal-title":"Autism"},{"issue":"5","key":"7847_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/0003-4819-146-5-200703060-00004","volume":"146","author":"K Kroenke","year":"2007","unstructured":"Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317\u201325.","journal-title":"Ann Intern Med"},{"issue":"6","key":"7847_CR33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1192\/bjp.bp.110.082727","volume":"198","author":"G Lewis","year":"2011","unstructured":"Lewis G, Mulligan J, Wiles N, Cowen P, Craddock N, Ikeda M, Grozeva D, Mason V, Nutt D, Sharp D, et al. Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. Br J Psychiatry. 2011;198(6):464\u201371.","journal-title":"Br J Psychiatry"},{"issue":"9","key":"7847_CR34","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"key":"7847_CR35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1192\/bjp.176.4.379","volume":"176","author":"KM Connor","year":"2000","unstructured":"Connor KM, Davidson JR, Churchill LE, Sherwood A, Foa E, Weisler RH. Psychometric properties of the Social Phobia Inventory (SPIN) New self-rating scale. Br J Psychiatry. 2000;176:379\u201386.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"7847_CR36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/aur.1461","volume":"8","author":"T Cadman","year":"2015","unstructured":"Cadman T, Spain D, Johnston P, Russell A, Mataix-Cols D, Craig M, Deeley Q, Robertson D, Murphy C, Gillan N, et al. Obsessive-compulsive disorder in adults with high-functioning autism spectrum disorder: what does self-report with the OCI-R tell us? Autism Res. 2015;8(5):477\u201385.","journal-title":"Autism Res"},{"issue":"18","key":"7847_CR37","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","volume":"282","author":"RL Spitzer","year":"1999","unstructured":"Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282(18):1737\u201344.","journal-title":"JAMA."},{"issue":"11","key":"7847_CR38","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1007\/s10803-015-2514-6","volume":"45","author":"SL Barrett","year":"2015","unstructured":"Barrett SL, Uljarevic M, Baker EK, Richdale AL, Jones CR, Leekam SR. The Adult Repetitive Behaviours Questionnaire-2 (RBQ-2A): a self-report measure of restricted and repetitive behaviours. J Autism Dev Disord. 2015;45(11):3680\u201392.","journal-title":"J Autism Dev Disord"},{"issue":"7","key":"7847_CR39","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/aur.2115","volume":"12","author":"SH Park","year":"2019","unstructured":"Park SH, Demetriou EA, Pepper KL, Song YJC, Thomas EE, Hickie IB, Glozier N, Guastella AJ. Validation of the 36-item and 12-item self-report World Health Organization Disability Assessment Schedule II (WHODAS-II) in individuals with autism spectrum disorder. Autism Res. 2019;12(7):1101\u201311.","journal-title":"Autism Res"},{"key":"7847_CR40","doi-asserted-by":"crossref","unstructured":"EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"issue":"2","key":"7847_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/016327879301600205","volume":"16","author":"CA Macera","year":"1993","unstructured":"Macera CA, Eaker ED, Jannarone RJ, Davis DR, Stoskopf CH. A measure of perceived burden among caregivers. Eval Health Prof. 1993;16(2):205\u201311.","journal-title":"Eval Health Prof"},{"issue":"6","key":"7847_CR42","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s11136-013-0616-1","volume":"23","author":"I Goranitis","year":"2014","unstructured":"Goranitis I, Coast J, Al-Janabi H. An investigation into the construct validity of the Carer Experience Scale (CES). Qual Life Res. 2014;23(6):1743\u201352.","journal-title":"Qual Life Res"},{"issue":"6","key":"7847_CR43","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/PSY.0000000000000322","volume":"78","author":"K Kroenke","year":"2016","unstructured":"Kroenke K, Wu J, Yu Z, Bair MJ, Kean J, Stump T, Monahan PO. Patient Health Questionnaire Anxiety and Depression Scale: initial validation in three clinical trials. Psychosom Med. 2016;78(6):716\u201327.","journal-title":"Psychosom Med"},{"key":"7847_CR44","doi-asserted-by":"publisher","unstructured":"Beasant L, Realpe A, Douglas S, Kenny L, Rai D, Mills N. Autistic adults\u2019 views on the design and processes within randomized controlled trials: The APRiCoT study. Autism. 2023 Oct 26:13623613231202432. https:\/\/doi.org\/10.1177\/13623613231202432. Online ahead of print.","DOI":"10.1177\/13623613231202432"},{"issue":"3","key":"7847_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/aut.2022.0027","volume":"5","author":"AX Realpe","year":"2023","unstructured":"Realpe AX, Mills N, Beasant L, Douglas S, Kenny L, Rai D. Lockdown experiences and views on future research participation of autistic adults in the UK during the first 6 months of the COVID-19 pandemic. Autism Adulthood. 2023;5(3):301\u201310.","journal-title":"Autism Adulthood"},{"key":"7847_CR46","unstructured":"Sealed Envelope. https:\/\/www.sealedenvelope.com\/. Accessed 20 Sept 2023."},{"issue":"12","key":"7847_CR47","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.jclinepi.2015.04.013","volume":"68","author":"KA Robinson","year":"2015","unstructured":"Robinson KA, Dinglas VD, Sukrithan V, Yalamanchilli R, Mendez-Tellez PA, Dennison-Himmelfarb C, Needham DM. Updated systematic review identifies substantial number of retention strategies: using more strategies retains more study participants. J Clin Epidemiol. 2015;68(12):1481\u20137.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"7847_CR48","first-page":"MR000008","volume":"2009","author":"PJ Edwards","year":"2009","unstructured":"Edwards PJ, Roberts I, Clarke MJ, Diguiseppi C, Wentz R, Kwan I, Cooper R, Felix LM, Pratap S. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev. 2009;2009(3):MR000008.","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"7847_CR49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"11","key":"7847_CR50","doi-asserted-by":"publisher","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","volume":"152","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726\u201332.","journal-title":"Ann Intern Med"},{"issue":"4","key":"7847_CR51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1191\/0962280205sm403oa","volume":"14","author":"G Dunn","year":"2005","unstructured":"Dunn G, Maracy M, Tomenson B. Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods. Stat Methods Med Res. 2005;14(4):369\u201395.","journal-title":"Stat Methods Med Res"},{"key":"7847_CR52","unstructured":"National Institute for Health and Care Excellence (NICE). Position statement on the EQ-5D-5L value set for England. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/technology-appraisal-guidance\/eq-5d-5l. Accessed 20 Sept 2023."},{"key":"7847_CR53","unstructured":"Curtis L, Burns A: Unit Costs of Health and Social Care 2017. In. Canterbury: Personal Social Services Research Unit, University of Kent.; 2017."},{"key":"7847_CR54","unstructured":"NHS Reference Costs. https:\/\/improvement.nhs.uk\/resources\/reference-costs\/. Accessed 20 Sept 2023."},{"key":"7847_CR55","unstructured":"British Medical Association., Joint Formulary Committee., Pharmaceutical Society of Great Britain.: British national formulary. In. London: British Medical Association."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07847-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07847-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07847-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T07:05:24Z","timestamp":1704956724000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07847-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7847"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07847-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3387261\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Oxford B REC (22\/SC\/0296) [UK], South Metropolitan Health Service Human Research Ethics Committee, Government of Western Australia RGS0000003578 [Australia].Written informed consent will be obtained from all participants. To enable remote delivery of the trial, this will be captured via a MHRA (UK) and NHMRC & TGA (Australia) compliant eConsent process. An approved paper (wet ink) equivalent will be available where eConsent is not feasible.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"A copy of the consent form for the main trial is attached as a Supplementary file\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"DSB has received research funding from several pharmaceutical and biotechnology companies (including Pfizer Ltd., the developers of sertraline). He has attended advisory boards hosted by Idorsia (daridorexant), Liva Nova (transcranial direct current stimulation), and Mundipharma (methoxyflurane), any honoraria being paid to University of Southampton. He has received editorial honoraria from Wiley publishers, for editorship of <i>Human Psychopharmacology<\/i>.TSB has provided a one off consultancy for Roche, the honorarium being paid to the University of Leicester. HL was previously paid for one hour of consultancy by BioMedical Insights (San Francisco) in relation to CDKL5 deficiency disorder. She has also consulted for Marinus, Acadia, Avenix, Orion, Avanex and Newron on topics unrelated to this project, and all remuneration has been paid to her department.RM has received honoraria for talks on management of ADHD from Takeda and MEdice Pharmaceuticals, the funds directed to his team.All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"37"}}